Besides a potential neuroprotective role in Parkinson’s disease, MAO-B inhibitors also reduce central dopamine metabolism and depletion and thereby provide a symptomatic benefit, particularly as an adjuvant to levodopa therapy [14]. This evidence concerns the gene MAOB and Parkinson disease.